Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human
endostatin) combined with AI chemotherapy in adjuvant treatment after radical resection of
recurrent soft tissue sarcoma.